Emergent BioSolutions Inc.
EBS | NYSE
$6.55
-$0.25 (-3.68%)
At close: Sep 21, 2026, 4:00 PM ET
$6.55
$0 (0.00%)
After-hours:
Sep 21, 2026, 4:18 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 742.9M | 1.04B | 1.05B | 1.12B | 1.77B | 1.58B |
Cost of Revenue | 392.3M | 668.2M | 689.3M | 644.5M | 980.4M | 714.2M |
Gross Profit | 350.6M | 375.4M | 360M | 473M | 793.2M | 863.1M |
Operating Income | 110.2M | -108.7M | -726.4M | -170M | 341.4M | 438.5M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 82.8M | -142.9M | -731.2M | -219M | 303.2M | 411.9M |
Net Income | 52.6M | -190.6M | -760.5M | -211.6M | 219.5M | 305.8M |
Selling & General & Admin | 186.6M | 298.7M | 356.7M | 339.5M | 348.7M | 304.1M |
Research & Development | 53.8M | 70.7M | 111.4M | 188.3M | 235.2M | 237.9M |
Other Expenses | n/a | 114.7M | 618.3M | 115.2M | -132.1M | -117.4M |
Operating Expenses | 240.4M | 484.1M | 1.09B | 643M | 451.8M | 424.6M |
Interest Expense | 59.3M | 71M | 87.9M | 37.3M | 34.5M | 31.3M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 632.7M | 1.15B | 1.78B | 1.29B | 1.43B | 1.14B |
Income Tax Expense | 30.2M | 47.7M | 29.3M | -7.4M | 83.7M | 106.1M |
Shares Outstanding (Basic) | 53.5M | 53M | 51.2M | 50.1M | 53.5M | 52.7M |
Shares Outstanding (Diluted) | 56.7M | 53M | 51.2M | 50.1M | 54.1M | 53.8M |
EPS (Basic) | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 | 5.79 |
EPS (Diluted) | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 | 5.67 |
EBITDA | 240.4M | 53.4M | -47M | 15.7M | 504.2M | 609.2M |
EBIT | 142.1M | -52.2M | -168.1M | -109.3M | 386M | 499.2M |
Depreciation & Amortization | 98.3M | 105.6M | 121.1M | 125M | 118.2M | 110M |
Add to Watchlist
Select watchlists to add or remove EBS